CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is pleased to announce its strategic priorities for calendar 2025 and the voting results from its annual general meeting of shareholders held on March 17, 2025 (the "Meeting") in Sarasota, Florida. The total number of shares represented in person or by proxy at the Meeting was 31,400,043, representin ...

Quipt Home Medical (NASDAQ: QIPT )(TSX: QIPT:CA ), a supplier of medical devices such as CPAP machines and home ventilators, has been the target of shareholder activism as of late. Two activist funds have accumulatedAnalyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other th ...

CINCINNATI, March 04, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the "Company" or "Quipt") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced that it has entered into a cooperation agreement (the "Agreement") with David Kanen, Philotimo Fund, LP and Kanen Wealth Management, LLC (collectively with their affiliates, "Kanen"), under which Kanen has agreed to withdraw its notice of its intent to solicit proxies in support of fou ...

Financial Data and Key Metrics Changes - Revenue for fiscal Q1 2025 was $61.4 million, a 2% decrease year-over-year from $62.6 million in fiscal Q1 2024 [19] - Adjusted EBITDA for Q1 2025 was $14 million with a margin of 22.8%, compared to $15.3 million and 24.5% margin in Q1 2024, representing an 8.7% decrease [22] - Net loss improved to $1.1 million or $0.03 per diluted share from a net loss of $1.5 million or $0.04 per diluted share in Q1 2024 [23] - Cash flow from continuing operations was $9.3 million for the three months ended December 31, 2024, compared to $10.6 million in the prior period [23] Business Line Data and Key Metrics Changes - The company completed 221,000 unique setups and deliveries in fiscal Q1 2025, a 3% increase from 215,000 in fiscal Q1 2024 [18] - Respiratory resupply setups and deliveries increased to 124,000 for the quarter, reflecting a 1% year-over-year growth [18] - Recurring revenue accounted for approximately 77% of total revenue in Q1 2025 [22] Market Data and Key Metrics Changes - The company has expanded to 135 locations across 26 states, serving over 314,000 active patients [6] - The regulatory environment remains stable, allowing for greater operational efficiency and confidence [14] Company Strategy and Development Direction - The company is focused on driving organic revenue growth, achieving operational net profit, generating positive cash flow, and expanding adjusted EBITDA and its margin [30] - Strategic initiatives include optimizing organizational structure, enhancing operational efficiencies, and exploring new market opportunities [31][32] - The company aims to leverage technology to improve operational performance and enhance workflow processes [33] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about steady demand across the product portfolio and the potential for growth in calendar 2025 [35] - The company is confident in its ability to deliver exceptional patient care and strengthen relationships with payers [15] - Management noted that most headwinds from previous changes in contracts and regulations are believed to be behind them [50] Other Important Information - The company has total credit capability of $32.4 million, including $11.4 million available on a revolving credit facility [24] - The company is managing its balance sheet prudently with a net leverage ratio of 1.5x [15] Q&A Session Summary Question: Impact of contract termination on revenue - The termination of a disposable supply contract is expected to be about a $2.5 million headwind for the entire calendar year [39] Question: Headwinds from capitated contracts - The larger impact from capitated contracts will be seen in the first half of fiscal 2025, with approximately $1 million in Q2 and lesser amounts in subsequent quarters [46] Question: Progression of margins throughout the year - The company aims for steady increases in EBITDA margins as they focus on organic growth [56] Question: Resupply business traction - The company is implementing strategies to improve catchment rates and compliance, which are expected to drive growth in the resupply business [72] Question: Medicare reimbursement concerns - Management is not currently aware of any changes that would negatively impact reimbursement, and there is hope for positive news regarding the 75-25 blended rate [77] Question: Bad debt expense under GAAP - Historically, bad debt expense was around 4% to 4.5%, and improvements are expected in the second half of 2025 [80] Question: Organic growth expectations - The company is targeting a return to 8% to 10% organic growth in 2025 [82]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 British Columbia, Canada N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 1019 Town Drive Wilder, KY 41076 (Address of principal executive offices, including zip code) (859) 878-2220 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPOR ...

Exhibit 99.1 QUIPT HOME MEDICAL REPORTS FIRST QUARTER FISCAL YEAR 2025 FINANCIAL RESULTS POSTS STRONG SEQUENTIAL IMPROVEMENT IN ADJUSTED EBITDA Cincinnati, Ohio – February 10, 2025 – Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 a ...

CINCINNATI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. ("Quipt" or the "Company") (NASDAQ:QIPT, TSX:QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced its first quarter fiscal year 2025 financial results and operational highlights. These results pertain to the three months ended December 31, 2024 and are reported in U.S. Dollars. Conference Call Quipt will host its Earnings Conference Call on Tuesday, February 11, 2025 at 10:00 a.m. ( ...

CINCINNATI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, acknowledges receipt of a notice from Philotimo Fund, LP, an entity affiliated with Kanen Wealth Management, LLC and David L. Kanen (“KWM”), purporting to provide notice of its intent to solicit proxies in support of four director candidates to the Company’s Board of Directors (the “Board”) in opposition to th ...

CINCINNATI, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, will announce its fiscal first quarter 2025 financial results on Monday, February 10, 2025, after market close. Gregory Crawford, Chief Executive Officer, and Hardik Mehta, Chief Financial Officer, will host a conference call for the investment community on Tuesday, February 11, 2025, at 10:00 a.m. (ET). The ca ...

Quipt Home Medical (NASDAQ: QIPT ) is one of those under-the-radar companies that answers a need in people’s daily life by delivering in-home respiratory care and durable medical equipment to 135 centers in 26 states. They’re all about respirators, and withThe mission of Grassroots Trading rests on the following principles: providing objective, unbiased, and balanced research, backed by solid data and completely void of emotional influences or preference for companies; focusing on small- to mid-cap companie ...